Interleukin 6 and tumour necrosis factor alpha serum levels in monoclonal gammopathy of undetermined significance.
The objectives of the present study were to compare the interleukin 6 (IL-6) and tumour necrosis factor-alpha (TNF-alpha) serum levels of individuals with monoclonal gammopathy of undetermined significance (MGUS) with those of healthy controls, and to ascertain the predictor value of these cytokines in the evolution from MGUS to multiple myeloma. After a median follow-up of 7 years from the initial cytokine measurements, nine patients with MGUS have evolved to a malignant condition. The actuarial probability of malignant transformation in patients with increased IL-6 and TNF-alpha was not significantly higher than in those with normal values.
Bladé
Joan
J
Institute of Hematology and Oncology, Farreras-Valentí Postgraduate School of Hematology, University of Barcelona, Villaroel 170, 08036 Barcelona, Spain. jblade@clinic.ub.es
Filella
Xabier
X
Montoto
Silvia
S
Bosch
Francesc
F
Rosiñol
Laura
L
Coca
Francesca
F
Giné
Eva
E
Nadal
Elisabeth
E
Aymerich
Marta
M
Rozman
María
M
Montserrat
Emili
E
D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D015850:Interleukin-6 / Q000097:blood*; D009101:Multiple Myeloma; D010265:Paraproteinemias / Q000097:blood*; D011336:Probability; D011379:Prognosis; D018709:Statistics, Nonparametric; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis*
D015415:Biomarkers; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha